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The prion protein PrP has a key role in transmissible spongiform encephalopathies but its biological
function remains largely unknown. Recently, a related protein, Shadoo, was discovered. Its biolog-
ical properties and brain distribution partially overlap that of PrP. We report that the Shadoo-
encoding gene knockdown in PrP-knockout mouse embryos results in a lethal phenotype, occurring
between E8 and E11, not observed on the wild-type genetic background. It reveals that these two
proteins play a shared, crucial role in mammalian embryogenesis, explaining the lack of severe phe-
notype in PrP-knockout mammals, an appreciable step towards deciphering the biological role of
this protein family.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The Prnp gene plays a pivotal role in transmissible spongiform
encephalopathies, encoding for a protein needed for prion replica-
tion and scrapie pathogenesis [1,2], an abnormal conformer of
which is the only known constituent of mammalian prions [3].
The cellular prion protein, PrPC, is a glycosyl-phosphatidyl-inositol
(GPI)-anchored cell surface protein with two sites of Asn-linked
glycosylation, expressed in a broad range of vertebrate tissues
[4]. The physiological function of PrPC remains unclear although
various functions have been suggested [5]. A neuroprotective role
has been documented as well as a potential implication in cell pro-
liferation and differentiation. PrPC temporal regulation highlighted
its possible involvement in embryogenesis [6–8]. However, Prnp-
knockout mice, beside slight circadian rhythm, hippocampal func-
tion and behavioural alterations, have no drastic phenotype [9–13],
even when PrPC is invalidated in adult neurons [14]. The lack of
PrPC did not apparently dramatically affect the development or
the behaviour of knockout Prnp cattle [15] or goat [16]. One ad-
vanced reason for such observations is the putative expression by
the host of a yet uncharacterised p protein that compensates for
allelic and/or induced alteration of PrP expression [17–19].chemical Societies. Published by E
aude), jean-luc.vilotte@jouy.
k.Recently, a PrP-related protein Shadoo having similarities with
a C-terminally truncated, GPI-anchored PrP was discovered
[20,21]. The highly conserved encoding gene, Sprn, is located on a
chromosome different from that of Prnp. Its expression was ana-
lysed in various species [21–24]. In the central nervous system,
Shadoo and PrPC were shown to have partially overlapping expres-
sion patterns. A positive correlation between cerebral and cerebel-
lar cortex expression of these two genes was reported in sheep
[25]. Expression of Shadoo was found to be altered in the brains
of prion-diseased mice [24] and to be potentially involved in hu-
man prion pathobiology [26]. Shadoo shares some neuro-protec-
tive properties with PrPC and thus is a good candidate for being
the hypothetical PrP-like protein p and a modulator for the biolog-
ical actions of normal and misfolded PrP [24,27]. According to
mouse EST databases (GenBank), Sprn is transcribed in the embryo
alongside Prnp. This study was aimed to assess if PrPC and Shadoo
share a function related with early embryogenesis.2. Materials and methods
Intra-perivitellin space injections of the lentivirus solutions
were done according to Lois et al. [28] on FVB/N and FVB/N Prnp
knockout (FVB.129-Prnp trn1Zrch) [9,29] mouse eggs. All sh-RNA
lentiviral vector solutions were purchased from Sigma with infec-
tious titers over 109 infectious units/ml (LS1: TRCN0000179960,
LS2: TRCN0000184740 and Lfox: TRCN0000086505). Animallsevier B.V. All rights reserved.
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Génie Génétique” recommendations.
Total RNA was isolated from whole mouse embryos and adult
brain using RNA Now (Biogentex Inc.) and 3 lg of puriﬁed RNA
was reverse transcribed with SuperScript II Reverse Transcriptase
kit (Invitrogen) according to the manufacturer’s protocol.
For RT-PCR analysis, cDNA was transcribed as described above.
Sprn was ampliﬁed using the primers 50-CTGGCTAGTGTATAGG-
TTTC-30 and 50-CTGCAATGAGGGAAAAGCCT-30 with 30 cycles of
95 C for 30 s, 55 C for 30 s and 72 C for 12 s.
Detection of sh-RNA in transgenic embryos was realised by
RT-PCR analysis. Five micrograms of total RNA was polyadenylated
using the Ambion PolyA Polymerase protocol (Ambion, Applied Bio-
systems). The polyadenylated RNA was reverse transcribed using a
RTQ primer (50-CGAATTCTAGAGCTCGAGGCAGGCGACATGGCTG-
GCTAGTTAAGCTTGGTACCGAGCTCGGATCCACTAGTCC(T)25VN) and
SuperScript II Reverse Transcriptase. RT-PCR analysis was per-
formed using a universal reverse primer (50-CGAATTCTAGAGCTC-
GAGGCAGG-30) and a forward primer speciﬁc for the sh-RNA
sequence (FoxL2: 50-CGGCATGTTCGAGAAGGGCA-30). The PCR con-
ditions comprised 40 cycles of 94 C for 30 s, 60 C for 30 s and 72 C
for 7 s.
Quantitative real-time PCR analysis was performed using ABI
PRISM 7000 Sequence Detection System (Applied Biosystems) and
SYBR Green (Applied Biosystems). Mouse Sprn and b-actin were
ampliﬁed using the primers 50-CTGGCTAGTGTATAGGTTTC-30 and
50-CTGCAATGAGGGAAAAGCCT-30 for Sprn and 50-CACCAGTCCGC-
CATGGATG-30 and 50-TCCCCACCATCACACCCTG-30 for b-actin,
respectively. These primerswere designed over exon–exon borders.
The PCR conditions used comprised 45 cycles at 95 C for 15 s and
60 C for 1 min. Each sample was analysed in triplicate and data
analysed using the Delta-Delta Ct method.
3. Results and discussion
3.1. In utero knockdown of Sprn can be lethal in the absence of Prnp
Two anti-mouse Sprn sh-RNA lentiviral vector solutions, LS1
and LS2, were used to knockdown the expression of murine Sprn
in both FVB/N and FVB/N Prnp-knockout mice. These sh-RNA are
under the transcriptional regulation of the ubiquitous U6 promoter
and each recognises a different target sequence located within the
30-UTR of Sprn. Viable transgenic mice were obtained with injec-
tions of lentivirus LS1 and LS2 on FVB/N and FVB/N Prnp-knockout
genotypes (Table 1A). These founder animals were analysed byTable 1
Effect of sh-RNA-mediated Sprn knockdown.
Lentivirus LS1a
Genetic background wtb KO
A: On the number and transgenic status of the injected animals
Transferred eggs 127 83
Nb. of animals born (% born/transferred) 33 (26.0) 14
Nb. of transgenic animals (% transgenic/born) 6 (18.2) 8 (
LS2a
wtb KO
B: On embryo reabsorption at E10.5
Implanted 101 95
Nb. of reabsorbed embryos (% reabsorbed/implanted) 49 (48.5) 73
Nb.: Number.
a Sprn sh-RNA (LS2) or FoxL2 sh-RNA (Lfox) lentivirus vectors.
b wt: Wild-type FVB/N mice.
c KO: FVB/N PrP-knockout mice.
d Signiﬁcance P value (Student t-test). NS: Not signiﬁcant.QPCR at 2 months of age and all showed signiﬁcant cerebellar Sprn
gene down-regulation, ranging from 50% to 90%, demonstrating
the functionality of the two sh-RNAs (Fig. 1). No correlation could
be made between the level of down-regulation and the genetic
background of the mouse.
A striking observation was the signiﬁcantly lower percentage of
animals born and the concomitant higher percentage of transgen-
ics obtained following injection of the anti-Sprn lentivirus in the
FVB/N Prnp-knockout versus the wild-type genotype (Table 1A).
The diminution of the number of animals born suggests a lethality
induced by the expression of the anti-Sprn sh-RNA in the absence
of PrP. Because two different sh-RNAs were used, this lethality is
unlikely to be related to an off-target phenomenon. Furthermore,
such an effect should have been detected in both genotypes.
Intriguingly, the percentage of transgenics obtained in the FVB/N
Prnp-knockout genotype was higher, suggesting that the lethal
phenotype affects non-transgenic animals more, i.e. injected ani-
mals with no integrated lentivirus, which appears contradictory
to being a consequence of the Sprn-down-regulation. In order to
further deﬁne the phenotype and to clarify this paradox, we as-
sessed the developmental stage at which the lethality occurs.
3.2. Evidence of an early embryonic lethality in injected FVB/N Prnp-
knockout embryos
Since Prnp expression is activated between E7 and E9 ([7,8],
BQ257016 in GenBank), the percentage of reabsorption was ana-
lysed at E10.5 following injection of LS2. In parallel a similar study
was performed following injection of anti-mouse FoxL2 sh-RNA
lentiviral vector suspension. This latter lentivirus (Lfox) was used
as a control since the knockout of the targeted gene was reported
not to be lethal [30]. The obtained results summarised in Table 1B
showed (i) a similar rate of reabsorption of the embryos injected
with either LS2 or Lfox on a FVB/N genotype and (ii) a signiﬁcantly
higher rate of reabsorption of embryos injected with LS2 on mouse
FVB/N Prnp knockout eggs, while no statistically signiﬁcant differ-
ence was found between the two genetic backgrounds with Lfox,
therefore arguing against a higher sensibility of one genetic back-
ground towards a lentiviral infection.
The FVB/N Prnp-knockout embryos not reabsorbed following
injection of the LS2 lentivirus were further analysed macroscopi-
cally. More than 80% of them were en route to being reabsorbed
or were smaller (Fig. 2A). Strikingly, the latter embryos had a
failure of closure of the cranial neural tube, a feature that was also
observed in a proportion of injected FVB/N Prnp+/ but not in FVB/NLS2a
c P valued wtb KOc P valued
291 102
(16.8) <0.05 54 (18.5) 4 (3.9) <0.001
57.1) <0.001 17 (31.5) 4 (100) <0.001
Lfoxb
c P valued wtb KOc P valued
56 41
(76.8) <0.001 28 (50.0) 16 (39.0) NS
Fig. 1. Sprn knockdown in the cerebellum of adult founder LS transgenic mice. QPCR was performed in triplicate using total RNA isolated from the cerebellum of adult founder
transgenic mice. The amount of Sprn RNA is expressed as an arbitrary value following b-actin normalisation and assuming a 100% level of expression in wild-type FVB/N mice.
The injected lentivirus (LS1 or LS2) and the genetic Prnp background of the mice are indicated. The number refers to the founder identiﬁcation.
Fig. 2. Abnormal neural development of FVB/N Prnp-knockout E10.5 embryos injected with Sprn sh-RNA lentivirus (LS2). (A, D and E) Macroscopic examination of injected
FVB/N Prnp-knockout embryos. Among the embryos that were not already reabsorbed at this stage (see Table 1B), 9 out of the 11 analysed were smaller or partially
reabsorbed (star in A). The smaller embryos had an abnormal developmental phenotype with a failure of closure of the cranial neural tube, leaving a region of open neural
folds (arrowhead in D and E). (B, F and G) Injected FVB/N Prnp+/ embryos. Three out of the 16 implanted embryos were smaller (star in B) and presented the same defect of
neural tube closure (arrowhead in F and G) as observed in PrP-knockout embryos. At a later developmental stage, E13, only normal embryos could be observed. (C and H)
Injected FVB/N embryos. Although some embryos (2 out of 14) were found to be slightly smaller (closed circle in C), none presented an abnormal developmental phenotype.
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tivirus albeit the number of abnormal embryos was reduced, con-
sistent with the seemingly lower efﬁciency of this vector (Table 1A;
Fig. 1). It suggests that a genotype with hypomorphic Prnp and Sprn
alleles can result in a neuronal defect, probably transient since it
was not observed in the born pups.
Our results indicate that the Sprn-knockdown-induced lethality
occurred at an early embryonic stage, after implantation and be-
fore E11 in FVB/N Prnp-knockout embryos. Since it is speciﬁc to
this genotype, this window can be further theoretically reduced
according to the published developmental regulation of Prnp
([7,8] and BQ257016 in GenBank) and to that observed for Sprn
(AI550081 in GenBank and Fig. 3A) to E8 to E11. The absence of
such a phenotype on FVB/N genetic background also suggests that,
as was observed for Prnp, absence of Sprn expression alone does
not affect normal embryonic development.3.3. Early embryonic Sprn down-regulation can be observed in the
absence of sh-RNA lentivirus integration
The observation that the lethal phenotype occurs in early
embryogenesis led us to assess if the persistence of transcription-
ally active non-integrated lentivirus and/or siRNA could explain
the abovementioned paradox, i.e. that it also affects ‘‘non-trans-
genic” individuals, with no integrated lentivirus. It is established
that non-integrated lentivirus can persist in infected cells and be
transcriptionally active [31–33]. Lentivirus-derived Lfox siRNA
was detected by RT-PCR in 10 out of the 10 E10.5 injected embryos
analysed (Fig. 3C), a result indicating that it was actually indepen-
dent from the retrovirus integration since only 36% of pups geno-
typed were transgenic for the lentivirus (data not shown).
Furthermore, Sprn down-regulation was detected in LS2 E9 em-
bryos, as compared to the non-injected controls (Fig. 3B). Finally,
Fig. 3. Sprn expression in embryos and its siRNA-induced knockdown. (A)
Expression proﬁle of Sprn during embryonic development. Detection of Sprn mRNA
by RT-PCR using total RNA from E7 to E9 embryos. Ad: adult cerebellum. (B)
Detection of Sprn mRNA from E10.5 FVB/N Prnp-knockout embryos non-injected
(NI) or injected with the LS2 lentivirus suspension (LS2). (C) Detection of the Lfox-
encoded siRNA by RT-PCR using total RNA isolated from whole E10.5 embryos. The
siRNA was detected in 10 out of 10 analysed embryos, implying that non-integrated
lentiviral vector DNA is transcribed. C: No RNA template.
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LS1 or LS2 were injected on the FVB/N Prnp-knockout genotype
might be explained by a lower susceptibility to sh-RNA-mediated
down-regulation of transgenic embryos, as a result of silencing
mechanisms known to frequently occur with lentiviral vectors
upon integration [34].
Overall, our ﬁndings provide strong evidence for a crucial role
for prion family proteins in early embryogenesis with the need
for either Prnp or Sprn expression between E8 and E11. They lend
support to the view that both proteins share biological functions
involved in the development of a normal embryo and that one
can compensate for the absence of the other. It thus gives a mech-
anistic explanation for the otherwise surprisingly healthy-looking
PrP-knockout mammals.
The detected transient abnormal embryonic phenotype found in
some of the surviving E10.5 embryos appears to involve a default
of closure of the cranial neural tube (Fig. 2). Based on the PrP
and Shadoo neuro-protective properties and the developmental
timescale, it is tempting to speculate that Prnp and Sprn are in-
volved in mammalian neurulation [35], for which a role for PrP
has already being suspected [36]. Incidentally, it mimics the poten-
tial role recently attributed to the Zebraﬁsh PrP-2 gene during
embryonic development (quoted in [37]).
Finally, our ﬁndings also highlight the need for careful examina-
tion of animals resulting from the injection of lentiviral vectors
that encode for genes affecting early embryonic events, regardless
of their transgenic status.
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